Aimovig OverviewErenumab, sold under the brand name Aimovig, is a medication which targets the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine. Erenumab was approved in May 2018 and was the first of a group of four CGRPR antagonists to be approved by the U.S. Food and Drug Administration (FDA) that year. It is a form of monoclonal antibody therapy in which antibodies are used to block the receptors for the protein CGRP,...
Read more Aimovig Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Erenumab
Recent Aimovig Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 70mg/ml
NDC Database Records for Aimovig: (4 results)Sorted by National Drug Code
- 55513-840 Aimovig 70 mg/ml Subcutaneous Injection by Amgen Inc
- 55513-841 Aimovig 70 mg/ml Subcutaneous Injection by Amgen Inc
- 55513-842 Aimovig 140 mg/ml Subcutaneous Injection, Solution by Amgen Inc
- 55513-843 Aimovig 140 mg/ml Subcutaneous Injection, Solution by Amgen Inc